Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Key Terms

rna interference medical

RNA interference is a natural cellular process that acts like a mute switch to reduce or silence the activity of a specific gene by targeting its messenger RNA, the blueprint used to make a protein. For investors, it matters because therapies and diagnostics that harness this mechanism can precisely block disease-causing proteins, creating new drug classes with high potential reward but also scientific, manufacturing and regulatory risks that affect company value.

trim medical

Trim means a deliberate reduction — for example, selling part of an investment position, cutting costs or lowering financial forecasts. Investors watch trims because they signal changes in risk, cash flow or future profits; like pruning a plant, a trim can be a maintenance move to preserve health or an early warning that something needs fixing, and either can move a stock’s price.

pharmacokinetics medical

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

pharmacodynamics medical

Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.

familial chylomicronemia syndrome medical

A rare inherited disorder in which the body cannot clear large fat particles from the bloodstream after meals, causing extremely high blood-fat levels and recurrent inflammation of the pancreas, severe abdominal pain, and other complications. It matters to investors because there are few effective treatments, so drugmakers, gene-therapy developers, and diagnostic firms pursuing solutions can see outsized commercial value, regulatory incentives, and volatile stock moves if clinical trials or approvals succeed or fail — like a tiny market where each customer can be highly profitable.

small interfering rna medical

Small interfering RNA (siRNA) are short, lab-made strands of genetic material that act like a mute button inside cells, binding to a specific genetic message and preventing a particular protein from being made. For investors, siRNA represents a drug technology with the potential to treat diseases by precisely turning off harmful genes, which can mean high development costs, regulatory hurdles, intellectual property value, and the possibility of breakthrough therapies that change market dynamics.

apoc3 medical

APOC3 is a protein made from the APOC3 gene that helps control how the body moves and clears fat called triglycerides in the bloodstream; think of it as a traffic cop that can slow the removal of fat from circulation. It matters to investors because medicines that lower or block APOC3 can sharply reduce triglyceride levels and cardiovascular risk, making it a high-value drug target and a potential catalyst for regulatory approvals, market opportunities, or clinical setbacks.

type 2 diabetes medical

Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

BofA Securities 2026 Healthcare Conference – May 12-14, 2026

Type: Investor Group Dinner
Date/Time: May 12, 2026

Type: Fireside Chat Presentation
Date/Time: May 13, 2026, 10:00 am PDT

TIDES USA Oligonucleotide & Peptide Therapeutics – May 11-14 in Boston, Massachusetts

Title: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC
Date/Time: May 13, 2026, 4:45 PM EDT
Presenter: Kayal Madhivanan

33rd European Congress on Obesity (ECO 2026) – May 12-15 in Istanbul, Türkiye

Title: Elevated Activin E levels correlate with insulin resistance and metabolic dysfunction in non-human primates and adult patients with obesity and type 2 diabetes
Date/Time: May 13-14; 1:00 PM – 3:00 PM
Presenter: Jane Kerr, MBChB, MPH, DRCOG

2026 RBC Capital Markets Global Healthcare Conference – May 19-20, 2026

Type: Fireside Chat Presentation
Date/Time: May 20, 2026, 9:00 am EDT

European Atherosclerosis Society (EAS 2026) Congress – May 24-27 in Athens, Greece

2 Oral Presentations:

Title: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN SUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT
Session: Late Breaker Clinical Abstracts
Date/Time: May 26, 2026, 5:00 AM – 5:15 PM
Presenter: Jennifer Hellawell, MD

Title: A CASE REPORT OF A PREGNANT WOMAN WITH FAMILIAL CHYLOMICRONEMIA SYNDROME TREATED WITH PLOZASIRAN, A SMALL INTERFERING RNA AGAINST APOC3
Session: EAS stage: Outreach and case presentations
Date/Time: May 26, 2026, 8:30 AM – 10:30 AM
Presenter: Ann Mertens, MD

European Association for the Study of the Liver (EASL 2026) – May 27-30 in Barcelona, Spain

Title: ARO‑INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity
Late Breaker Poster Session
Presenter: Rinki Murphy, MBChB, PhD

Presentation materials and webcast links, if applicable, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

For more information, please visit arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company’s email list and receive news directly, please visit ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504575415/en/

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com

Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com

Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com

Source: Arrowhead Pharmaceuticals, Inc.